|1.||Tomer, Kenneth B: 1 article (05/2008)|
|2.||Deterding, Leesa J: 1 article (05/2008)|
|3.||Mason, Ronald P: 1 article (05/2008)|
|4.||Ehrenshaft, Marilyn: 1 article (05/2008)|
|5.||Jiang, Jinjie: 1 article (05/2008)|
|6.||Siraki, Arno G: 1 article (05/2008)|
|7.||Bonini, Marcelo G: 1 article (05/2008)|
|8.||He, Y L: 1 article (06/2001)|
|9.||Kitada, N: 1 article (06/2001)|
|10.||Hori, R: 1 article (06/2001)|
|1.||Cardiac Arrhythmias (Arrythmia)
06/12/1979 - "Ten patients with persistent ventricular arrhythmia were studied in a comparison of the antiarrhythmic efficacy of N-acetylprocainamide (NAPA) and procainamide (PA). "
05/01/1989 - "Class III agents clofilium (0.5 mg.kg-1), d-sotolol (3.2 approximately 20 mg.kg-1), and N-acetylprocainamide (15 approximately 120 mg.kg-1) prolonged the CL by 14(4), 16(5), and 19(7)% and terminated the arrhythmia in all trials. "
12/01/1986 - "Arrhythmia control by selective lengthening of cardiac repolarization: role of N-acetylprocainamide, active metabolite of procainamide."
07/01/1981 - "Acetylprocainamide was used to treat 11 patients with previous procainamide-induced lupus syndrome for their cardiac arrhythmias. "
06/04/1990 - "Procainamide proved effective in cardiac arrhythmias in 14 patients (66.7%) with statistical significance in the acute myocardial infarctions; blood serum procainamide plus N-acetylprocainamide levels being were below the therapeutical range. "
|2.||Atrial Flutter (Flutter, Atrial)
04/01/1989 - "Therefore, large-scale blinded studies of the efficacy of N-acetylprocainamide in the suppression of atrial flutter may be warranted."
04/01/1989 - "Of the 12 receiving N-acetylprocainamide (eight randomized and four crossovers), one (8%) failed therapy due to side effects, but none had atrial flutter. "
05/01/1988 - "In the atria, N-acetylprocainamide induced significant increases in effective refractory period (+27%, p less than 0.01), functional refractory period (+22%, p less than 0.01), and in atrial flutter cycle length (+13%, p less than 0.01). "
12/01/1987 - "Effect of procainamide and N-acetylprocainamide on atrial flutter: studies in vivo and in vitro."
05/01/1988 - "Effects of N-acetylprocainamide and recainam in the pharmacologic conversion and suppression of experimental canine atrial flutter: significance of changes in refractoriness and conduction."
|3.||Acute Kidney Injury (Acute Renal Failure)
06/01/2001 - "Quantitative estimation of renal clearance of N-acetylprocainamide in rats with various experimental acute renal failure."
06/01/2001 - "A variety of experimental acute renal failure (ARF) in rats were prepared and N-acetylprocainamide (NAPA) was used as a model drug. "
07/01/1988 - "The characteristics of exsorption and/or excretion of procainamide and its metabolite, N-acetylprocainamide (NAPA), into the small intestinal lumen in both normal rats and rats with acute renal failure (ARF rats) induced by uranyl nitrate were investigated by an in situ single-pass perfusion technique. "
07/01/1988 - "Transport of procainamide and N-acetylprocainamide from blood into the intestinal lumen and intestinal dialysis by oral activated charcoal in rats with acute renal failure."
|5.||Ventricular Premature Complexes (Premature Ventricular Contraction)
05/01/1977 - "Ten patients with chronic premature ventricular contractions (PVCs) received short-term oral therapy with N-acetylprocainamide (NAPA) to determine its antiarrhythmic efficacy and side effects under the conditions of a placebo-controlled, dose-ranging trial. "
05/01/1977 - "Dose-ranging trial of N-acetylprocainamide in patients with premature ventricular contractions."
01/01/1983 - "Higher correlation coefficients between numbers of premature ventricular contractions (PVCs) and the plasma concentrations of procainamide or N-acetylprocainamide were observed in 3 or more successive PVCs than in individually occurring PVCs. "
05/01/1990 - "In a small number of noncomparative and placebo-controlled short term therapeutic trials acecainide markedly reduced premature ventricular beats and prevented induction of ventricular tachycardia in more than 70% of patients following intravenous administration and in about 50% after oral administration. "
|7.||Sotalol (Sotalol Hydrochloride)
|3.||Renal Dialysis (Hemodialysis)